Discover Kymera Therapeutics' Q3 2025 earnings, clinical trial milestones in immunology, and strategic Gilead partnership.

A new study details howPresident Trump's tariffs could make many things more expensive this holiday season. Here's a look at the Trump tariffs impact.

Fiserv is a critical fintech player facing short-term challenges but remains essential and undervalued. Read why now is the ...

Safe Pro Group Inc. (Nasdaq: SPAI) ("Safe Pro" or the "Company"), a leader in artificial intelligence (AI)-powered defense ...

After 10 games, we now have enough data to predict every Premier League team's final spot in the standings for the 2025-26 season.

As Big Tech’s reach grows, Michael Steinberger’s portrait of Palantir’s enigmatic boss offers a timely study of surveillance ...

D espite millions of employees being called back to the office—even on a partial basis—the desire for remote work remains ...

India continues to stand out among developing economies, with analysts expecting capital to shift from China to India.

Zohran Mamdani, a 34-year-old Democratic Socialist, has mounted an unprecedented campaign for New York City Mayor, ...

In August 2025, Canada rejected a record 74% of Indian student visa applications — more than double the rate from 2023. The ...